Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             318 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A1.17 Activity of cefditoren compared with other β-lactams against respiratory tract pathogens throughout china from 2000 – 2003 2005
 26 S1 p. S70-S71
2 p.
 artikel
2 A7.18 Antibacterial activity of arylcarbonyl and arylsulfonyl N-linked 5-triazolylmethyl oxazolidinones 2005
 26 S1 p. S83-S84
2 p.
 artikel
3 A7.2 Antibacterial effect of mupirocin versus Helicobacter pylori in vitro 2005
 26 S1 p. S78-S79
2 p.
 artikel
4 A1.9 Antimicrobial activity of certain drugs against Streptococcus agalactiae strains in a general hospital of Caracas, Venezuela 1997–2003 2005
 26 S1 p. S68-
1 p.
 artikel
5 A1.3 Antimicrobial resistance of Escherichia coli to beta-lactams is age-dependent: A study of strains isolated from age-specific groups, west general hospital of Caracas, Venezuela, 1997–2003 2005
 26 S1 p. S65-S66
2 p.
 artikel
6 A1.2 Antimicrobial resistance of Pseudomonas aeruginosa isolated from infections in children, west general hospital of Caracas, Venezuela, 1997–2003 2005
 26 S1 p. S65-
1 p.
 artikel
7 A1.5 Antimicrobial susceptibility and resistance of non-aeruginosa Pseudomonas spp. at west general hospital, Caracas, Venezuela, 1997–2003 2005
 26 S1 p. S66-S67
2 p.
 artikel
8 A1.15 Antimicrobial susceptibility patterns among gram-negative bacilli causing intraabdominal infections in Asia Pacific countries: Results from smart 2003 2005
 26 S1 p. S70-
1 p.
 artikel
9 A1.32 Bacterial spectrum and antibiotic resistance of uropathogens in hospitalized urological patients with urinary tract infections (1994–2004) and consequences for empiric antibiotic therapy 2005
 26 S1 p. S75-S76
2 p.
 artikel
10 A1.7 Bacteriology and antimicrobial susceptibility of strains isolated from recreational swimming pools of two provinces of central Venezuela, 2003 2005
 26 S1 p. S67-
1 p.
 artikel
11 A1.28 Carriage of Streptococcus pneumoniae in primary school children in a minority population in a mountainous region of Guangxi province of China 2005
 26 S1 p. S74-
1 p.
 artikel
12 A1.8 Citrobacter, serratia and providencia antimicrobial resistance patterns in a general hospital of Caracas, Venezuela 1997–2003 2005
 26 S1 p. S68-
1 p.
 artikel
13 A1.20 Comparative in vitro antibacterial activity of cefditoren and other antibacterial agents against major causative organisms of skin and respiratory tract infections 2005
 26 S1 p. S71-S72
2 p.
 artikel
14 A1.27 Comparative minimal inhibitory and resistance prevention drug concentrations of azithromycin, clarithromycin, erythromycin and telithromycin against 260 clinical isolates of Streptococcus pneumoniae 2005
 26 S1 p. S74-
1 p.
 artikel
15 A1.13 Comparative study of In Vitro activity of carbapenems and other β-lactams against Staphylococcus aureus, S. epidermidis, Pseudomonas aeruginosa and enterobacteriaceae isolated from blood 2005
 26 S1 p. S69-S70
2 p.
 artikel
16 A7.13 Comparison of antibacterial activity of cefditoren and other antibacterials against Streptococcus pneumoniae including penicillin-resistant strains 2005
 26 S1 p. S82-
1 p.
 artikel
17 A1.19 Efficacy and safety of polymyxin B in the treatment of infections caused by multidrug-resistant Acinetobacter baumanii and Pseudomonas aeruginosa: A retrospective review 2005
 26 S1 p. S71-
1 p.
 artikel
18 A1.23 Emergence of Candida glabrata resistance to itraconazole 2005
 26 S1 p. S72-S73
2 p.
 artikel
19 A1.25 ESBL-producing strains of E. coli in Hong Kong 2005
 26 S1 p. S73-
1 p.
 artikel
20 A1.33 Evaluation of antibiotic susceptibility of Viridans Streptococci by the etest versus agar dilution method 2005
 26 S1 p. S76-
1 p.
 artikel
21 A1.30 Evaluation of three low cost methods for rapid detection of drug susceptibility in Mycobacterium tuberculosis 2005
 26 S1 p. S75-
1 p.
 artikel
22 A5.1 Extract Pelargonium Sidoides (EPs® 7630) improves opsonophagocytosis 2005
 26 S1 p. S77-S78
2 p.
 artikel
23 A1.18 Genetic characterization of resistant phonotypes in pneumococcal isolates, Thailand 2005
 26 S1 p. S71-
1 p.
 artikel
24 A7.9 Global in vitro antibacterial activity against Gram-positive and Gram-negative pathogens — tigecycline evaluation surveillance trial (T.E.S.T.) 2005
 26 S1 p. S81-
1 p.
 artikel
25 A3.1 Glomerular filtration rate circadian rhythm: Its relationship to aminoglycoside induced nephrotoxicity 2005
 26 S1 p. S77-
1 p.
 artikel
26 A7.15 Identification and characterization of the molecular targets for the novel antifungal drug HK293 2005
 26 S1 p. S82-S83
2 p.
 artikel
27 A7.1 Influence of linezolid on nitric oxide production by lipopolysaccaride stimulation 2005
 26 S1 p. S78-
1 p.
 artikel
28 A7.3 Inhibition of SARS coronavirus 3C-like protease by Isatis indigotica root and plant-derived phenolic compounds 2005
 26 S1 p. S79-
1 p.
 artikel
29 A7.5 In Vitro antibacterial activity against Gram-positive and Gram-negative pathogens in Asia - Tigecycline evaluation surveillance trial (T.E.S.T.) 2005
 26 S1 p. S79-
1 p.
 artikel
30 A7.7 In Vitro antibacterial activity against Gram-positive and Gram-negative pathogens in Europe — tigecycline evaluation surveillance trial (T.E.S.T.) 2005
 26 S1 p. S80-
1 p.
 artikel
31 A7.4 In Vitro antibacterial activity of DX-619, a novel des-fluoro(6)-quinolone, against multidrug-resistant gram-positive bacteria 2005
 26 S1 p. S79-
1 p.
 artikel
32 A7.8 In Vitro antimicrobial activity against Gram-positive and Gram-negative pathogens in the united states — tigecycline evaluation surveillance trial (T.E.S.T.) 2005
 26 S1 p. S80-S81
2 p.
 artikel
33 A7.16 In Vitro antimicrobial activity of cefditoren against Streptococcus pneumoniae and Haemophilus influenzae clinical isolates 2005
 26 S1 p. S83-
1 p.
 artikel
34 A1.11 In vitro susceptibility testing and minimum inhibitory concentration of Vibrio cholerae 01 biotype El Tor strains associated with an outbreak of cholera in Manipal, Southern India 2005
 26 S1 p. S69-
1 p.
 artikel
35 A1.1 Macrolide and ketolide resistance in a catchment of group C and group G hemolytic streptococci 2005
 26 S1 p. S65-
1 p.
 artikel
36 A1.16 Methicillin-resistant staphylococcal infections among patients with odontogenic infections 2005
 26 S1 p. S70-
1 p.
 artikel
37 A7.11 Newer and older drugs in the treatment of chagas' disease — An overview of new potential therapies 2005
 26 S1 p. S81-S82
2 p.
 artikel
38 A7.6 Novel biotherapeutics from Lactobacillus acidophilus USTCMS 1073 exhibiting potent inhibitory activity against bacteria, filamentous fungi and Candida albicans 2005
 26 S1 p. S80-
1 p.
 artikel
39 A7.19 Pharmacokinetics of telithromycin in plasma and soft tissues after single dose administration to healthy volunteers 2005
 26 S1 p. S84-
1 p.
 artikel
40 A1.26 Prevalence and type of erythromycin resistance in clinical isolates of Streptococcus pneumoniae in Hong Kong 2005
 26 S1 p. S73-S74
2 p.
 artikel
41 A1.21 Prevalence of aminoglycoside resistance genes in recent clinical isolates of enterococci in a Japanese hospital 2005
 26 S1 p. S72-
1 p.
 artikel
42 A1.22 Prevalence of tetracycline resistance genes in clinical isolates of enterococci in a Japanese hospital 2005
 26 S1 p. S72-
1 p.
 artikel
43 A8.1 Rapid rabies antibody response after priming dose of rabies vaccine 2005
 26 S1 p. S84-
1 p.
 artikel
44 A2.2 Review of clinical studies with a modern combination of amoxicillin (AX) + sulbactam (SB) (AXS) 2005
 26 S1 p. S76-S77
2 p.
 artikel
45 A2.1 Review of pharmacodynamic/pharmacokinetic (PD/PK) studies with a modern combination of amoxicillin (AX) + sulbactam (SB) (AXS) 2005
 26 S1 p. S76-
1 p.
 artikel
46 A1.6 Salmonella and shigella antimicrobial resistance patterns in a general hospital of Caracas, Venezuela 1997–2003 2005
 26 S1 p. S67-
1 p.
 artikel
47 A1.12 Self-medication with antibiotics in the general slovenian population 2005
 26 S1 p. S69-
1 p.
 artikel
48 A3.2 Serum concentration of pyrazinamide (PZA) in children taking an oral suspension for tuberculosis: A therapeutic drug monitoring 2005
 26 S1 p. S77-
1 p.
 artikel
49 A5.2 Stimulation of humoral systemic and mucosal immunity in patients with inflammations of the oral mucosa and parodont after treatment with a polybacterial immunomodulator 2005
 26 S1 p. S78-
1 p.
 artikel
50 A1.4 Surveillance analysis of decreasing susceptibility of Staphylococcus aureus against vancomycin according to a mathematical model, west general hospital of Caracas, Venezuela, 1997–2003 2005
 26 S1 p. S66-
1 p.
 artikel
51 A1.31 Susceptibility to cefepime of gram-negative bacilli isolated in a university hospital laboratory in Malaysia 2005
 26 S1 p. S75-
1 p.
 artikel
52 A1.29 Telithromycin susceptibility and macrolide resistance mechanisms of pneumococcal strains isolated from pediatric patients in southwestern Japan 2005
 26 S1 p. S74-S75
2 p.
 artikel
53 A7.12 The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections: Results of pooled clinical trial data 2005
 26 S1 p. S82-
1 p.
 artikel
54 A7.17 The In Vitro Bioactivity of Ipomoea muricata (Tonkin) crude extract against methicillin-resistant Staphylococcus aureus (MRSA) 2005
 26 S1 p. S83-
1 p.
 artikel
55 A7.10 Therapeutic efficacy of parenteral or oral DX-619, a novel des-fluoro(6)-quinolone, in MRSA infection models 2005
 26 S1 p. S81-
1 p.
 artikel
56 A1.24 Trends in prevalence and antibacterial susceptibility of bacteria isolated from hematological patients with intravenous lines: 5 years' experience 2005
 26 S1 p. S73-
1 p.
 artikel
57 A1.10 Urinary bactericidal activity of linezolid against gram-positive cocci in comparison with other oral antibiotics 2005
 26 S1 p. S68-S69
2 p.
 artikel
58 Author index 2005
 26 S1 p. S113-S116
4 p.
 artikel
59 B6.6 A case report on a patient with ascites, prolonged fever, hypercalcemia and elevated serum CA-125: A case of malignancy versus granulomatous disease 2005
 26 S1 p. S89-
1 p.
 artikel
60 B2.3 A comparative study of the efficacy of oral ribavirin for crimean-congo hemorrhagic fever in patients treated during the initial 5 days vs after 5 days of the disease, Southeast Iran 2005
 26 S1 p. S85-
1 p.
 artikel
61 B4.1 Clinical efficacy of chloroquine/primaquine against Plasmodium vivax infections in hospitalized children from sucre, Venezuela 2005
 26 S1 p. S87-
1 p.
 artikel
62 B6.7 Comparison of six month versus four month regimens of chemotherapy for smear positive pulmonary tuberculosis 2005
 26 S1 p. S89-
1 p.
 artikel
63 B2.5 Current clinical and microbiological profile of infective endocarditis in UERMMMC 2005
 26 S1 p. S85-
1 p.
 artikel
64 B6.3 Drug susceptibility testing of Mycobacterium tubercolosis by agar proportion method using lowenstein-jensen and middlebrook 7H10 with drug containing disk media 2005
 26 S1 p. S88-
1 p.
 artikel
65 B2.1 Emerging infection at the UST hospital: Burkholderia cepacia bacteremia 2005
 26 S1 p. S85-S85
1 p.
 artikel
66 B6.1 Incidence of hepatotoxicity due to antituberculosis medication and assessment of risk factors, Zahedan, Iran 2005
 26 S1 p. S87-S88
2 p.
 artikel
67 B3.3 Intestinal parasitic infections in AIDS patients at the okomfo anokye teaching hospital, Kumasi-Ghana 2005
 26 S1 p. S87-
1 p.
 artikel
68 B2.6 The changing epidemiology of Staphylococcus aureus endocarditis — experience of a large london teaching hospital trust 2005
 26 S1 p. S86-
1 p.
 artikel
69 B3.1 The incidence of oro-pharyngeal abnormalities in children and teenagers on antiretroviral chemotherapy 2005
 26 S1 p. S86-
1 p.
 artikel
70 B3.2 The role of the viral genotype in hepatitis C virus (HCV) and human deficiency virus-1 (HIV-1) co-infected patients 2005
 26 S1 p. S86-S87
2 p.
 artikel
71 B6.2 Two-year experience at a pediatric tuberculosis (TB) clinic of a tertiary government hospital 2005
 26 S1 p. S88-
1 p.
 artikel
72 B6.4 Use of whole blood inteferon-gamma (QuantiFERON-TB GOLD) as a tool for contact investigation of exposure to tuberculosis in healthcare workers 2005
 26 S1 p. S88-S89
2 p.
 artikel
73 C14.5 Acute pyelonephritis in the renal graft: A diagnostic challenge 2005
 26 S1 p. S98-S99
2 p.
 artikel
74 C1.1 Analysis of bacterial strains cultured from cerebrospinal fluids of patients hospitalized in a tertiary care hospital in 1998–2004 2005
 26 S1 p. S89-S90
2 p.
 artikel
75 C14.9 Analysis of contemporary urinary tract E. coli isolates by minimal inhibitory and mutant prevention concentration testing 2005
 26 S1 p. S100-
1 p.
 artikel
76 C6.5 Characteristics of Staphylococcus epidermidis bacteremia 2005
 26 S1 p. S92-
1 p.
 artikel
77 C15.2 Characterization of the dengue viral helicase as a target for anti-viral drug development 2005
 26 S1 p. S102-
1 p.
 artikel
78 C10.2 Clinical effect of intravenous ciprofloxacin on hospital-acquired pneumonia 2005
 26 S1 p. S95-
1 p.
 artikel
79 C6.7 Clinical profile and correlates of mortality of Burkholderia cepacia bacteremia among adult patients at St. Luke's medical center 2005
 26 S1 p. S93-
1 p.
 artikel
80 C10.1 Comparative effectiveness of amoxycillin and azithromycin in treatment of adult outpatients with mild-moderate community-acquired pneumonia in Ukraine 2005
 26 S1 p. S94-S95
2 p.
 artikel
81 C14.11 Comparison of the serum sensitivity and antibiotic susceptibility of uropathogenic Escherichia coli strains isolated from different diagnostic groups 2005
 26 S1 p. S101-
1 p.
 artikel
82 C14.3 Concentrations in plasma and urinary excretion of ciprofloxacin XR (1,000 milligrams) versus those of levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose 2005
 26 S1 p. S98-
1 p.
 artikel
83 C14.4 Concentrations in plasma, urinary excretion, and bactericidal activity of levofloxacin (500) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose 2005
 26 S1 p. S98-
1 p.
 artikel
84 C15.3 Dengue fever and dengue hemorrhagic fever in pregnancy 2005
 26 S1 p. S102-
1 p.
 artikel
85 C3.2 Detection of Clostridium difficile and its toxin A (TCDA) in stool specimens from hospitalized patients 2005
 26 S1 p. S90-
1 p.
 artikel
86 C12.1 Determination of the frequency and antimicrobial resistance of Mycoplasma hominis and Ureaplasma urealyticum among women with vaginal discharge 2005
 26 S1 p. S95-
1 p.
 artikel
87 C14.10 Efficacy and safety of gatifloxacin on the urinary tract infections in Korean usual practice 2005
 26 S1 p. S100-
1 p.
 artikel
88 C10.3 Etiology and clinical features of community-acquired pneumonia in hospitalized adult patients at a medical center in Southern Taiwan 2005
 26 S1 p. S95-
1 p.
 artikel
89 C3.1 Evaluation of bacterial flora and its susceptibility to antimicrobials in surgical patients with acute pancreatitis 2005
 26 S1 p. S90-
1 p.
 artikel
90 C8.2 Exploring the common mechanism of dengue NS3 protease trans-activation by NS2B cofactor from flaviviruses 2005
 26 S1 p. S94-
1 p.
 artikel
91 C8.1 Focal infections due to Salmonella spp: Report of eight cases and review of literature 2005
 26 S1 p. S94-
1 p.
 artikel
92 C14.1 Increasing antimicrobial resistance patterns of community-acquired and hospital-acquired uropathogens 2005
 26 S1 p. S97-
1 p.
 artikel
93 C14.6 Long-term antibiotic treatment for patients with acute “non complicated” pyelonephritis: Effect on kidney scar formation 2005
 26 S1 p. S99-
1 p.
 artikel
94 C6.1 Mycological findings upon admission to a non-surgical ICU — A prospective study 2005
 26 S1 p. S91-
1 p.
 artikel
95 C13.2 Rapid alternative methods for detection of rifampicin resistance in Mycobacterium tuberculosis 2005
 26 S1 p. S96-
1 p.
 artikel
96 CR.1 Aspergillosis: A case series 2005
 26 S1 p. S111-
1 p.
 artikel
97 C6.4 Reduction in neonatal bacteremia and mortality rates using a simple set of interventions in a NICU in the Philippines 2005
 26 S1 p. S92-
1 p.
 artikel
98 C13.3 Risk factors for surgical site infections following coronary artery bypass graft surgery in singapore: Preliminary results of a prospective observational study 2005
 26 S1 p. S96-S97
2 p.
 artikel
99 C14.12 Risk factors for urinary tract infections due to extended-spectrum β-lactamase producing Escherichia coli in Children 2005
 26 S1 p. S101-
1 p.
 artikel
100 C6.8 Risk factors of early- and late-onset ventilator-associated pneumonia and their influence on mortality in the ICU setting 2005
 26 S1 p. S93-
1 p.
 artikel
101 CR.2 Tuberculosis of the cervix uteri mimicking cervical malignancy: A case report 2005
 26 S1 p. S111-S112
2 p.
 artikel
102 C14.7 Significance of symptomatic and asymptomatic nosocomial urinary tract infections in a surgical intensive care unit. What are the consequences? 2005
 26 S1 p. S99-
1 p.
 artikel
103 C6.6 Successful treatment of Candida albicans endocarditis with caspofungin: A case report 2005
 26 S1 p. S92-
1 p.
 artikel
104 C6.2 Susceptibility of causative organisms isolated from Japanese patients with nosocomial pneumonia against antibacterial agents 2005
 26 S1 p. S91-
1 p.
 artikel
105 C12.2 The comparison of gram staining, culture and polymerase chain reaction (PCR) in the diagnosis of gonorrehea 2005
 26 S1 p. S96-
1 p.
 artikel
106 C13.1 The efficacy of antibiotherapy in suppurations of the submandibular area 2005
 26 S1 p. S96-
1 p.
 artikel
107 C4.1 The efficacy of lamivudine in the treatment of chronic hepatitis B in Southeast of Iran 2005
 26 S1 p. S90-
1 p.
 artikel
108 C7.1 The profile of sputum culture in patients with productive cough 2005
 26 S1 p. S93-S94
2 p.
 artikel
109 C6.3 The safety of reusing T-pieces in weaning patients from ventilators 2005
 26 S1 p. S91-S92
2 p.
 artikel
110 C14.8 Urinary pathogens and antibiotic susceptibility over twenty years 2005
 26 S1 p. S99-S100
2 p.
 artikel
111 C15.1 Varicella in immunocompromised filipino children: A six-year experience 2005
 26 S1 p. S101-
1 p.
 artikel
112 C14.2 Virulence properties in E. coli strains in patients with diabetis mellitus type-2 and asymptomatic bacteriuria — results of a multiplex-PCR-analysis in uropathogenic microorganisms 2005
 26 S1 p. S97-
1 p.
 artikel
113 D2.4 Antiviral efficacies of nucleic acids against acute viral infections 2005
 26 S1 p. S104-S105
2 p.
 artikel
114 D2.1 Immune effects of bulgarian oral polybacterial immunomodulators “Respivax”, “Urostim” and “Dentavax” 2005
 26 S1 p. S103-S104
2 p.
 artikel
115 D1.3 Methicillin-resistant Staphylococcus aureus in a veteran population over 12 years: Persistence and re-infection 2005
 26 S1 p. S103-
1 p.
 artikel
116 D1.2 Nasopharyngeal carriage of antimicrobial resistant Streptococcus pneumoniae and Haemophilus influenzae amongst children in day-care centers in Singapore 2005
 26 S1 p. S102-S103
2 p.
 artikel
117 D2.2 Quality improvement project on antibiotic prophylaxis in caesarean section 2005
 26 S1 p. S104-
1 p.
 artikel
118 D1.1 The incidence of Clostridium difficile-associated diarrhea in the adult intensive care units of the UP-Philippine general hospital: A case-control study 2005
 26 S1 p. S102-
1 p.
 artikel
119 D2.3 The In Vitro antimicrobial activity of human colostrum against common nursery isolates as compared to selected broad spectrum antimicrobials 2005
 26 S1 p. S104-
1 p.
 artikel
120 E3.1 Comparison of methods for ESBL detection 2005
 26 S1 p. S105-S106
2 p.
 artikel
121 E2.1 Rapid identification of human adenovirus types 3 and 7 from respiratory specimens via multiplex type-specific polymerase chain reaction 2005
 26 S1 p. S105-
1 p.
 artikel
122 E4.1 Seroprevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae among children in a multi-ethnic population of Singapore 2005
 26 S1 p. S106-
1 p.
 artikel
123 E1.1 Telomerase gene amplification in relation to telomerase activity and expression in selected tumors 2005
 26 S1 p. S105-
1 p.
 artikel
124 F2.2 Does dengue fever offer protection against a massive myocardial infarction? A case report 2005
 26 S1 p. S107-
1 p.
 artikel
125 F2.1 Doxycycline hyclate treatment and periodontal candida infection in diabetes 2005
 26 S1 p. S107-
1 p.
 artikel
126 F2.3 Focal infection in oral cavity of patient with extrasystolic heart arrhythmia 2005
 26 S1 p. S107-
1 p.
 artikel
127 F2.4 Intracellular activity of ampicillin, azithromycin, telithromycin, ciprofloxacin and moxifloxacin against non-typeable Haemophilus influenzae 2005
 26 S1 p. S107-S108
2 p.
 artikel
128 Foreword Tupasi, Thelma E.
 2005
 26 S1 p. iii-
1 p.
 artikel
129 F1.1 Risk assessment of adult patients with febrile neutropenia and malignancies 2005
 26 S1 p. S106-
1 p.
 artikel
130 F3.2 Scytalidium dimidiatum subcutaneous dermatomycosis in an immunocompromised child with acute lymphoblastic leukemia 2005
 26 S1 p. S108-
1 p.
 artikel
131 F1 1st forum 1.1. National status of tuberculosis, malaria, AIDS 2005
 26 S1 p. S8-
1 p.
 artikel
132 F5 1st Forum 1.5. The economic burden of tuberculosis 2005
 26 S1 p. S9-
1 p.
 artikel
133 F2 1st forum 1.2. The global fund projects in the Philippines 2005
 26 S1 p. S8-
1 p.
 artikel
134 F3 1st forum 1.3. The global fund to fight AIDS, tuberculosis and malaria 2005
 26 S1 p. S8-S9
2 p.
 artikel
135 F4 1st forum 1.4. The Philippine partnership to fight tuberculosis, malaria and AIDS 2005
 26 S1 p. S9-
1 p.
 artikel
136 F3.1 The immunomodulator in the therapy of HIV, HSV and HCV infection 2005
 26 S1 p. S108-
1 p.
 artikel
137 G2.2 Comparison of the methods for the synthesis of cytokine genes 2005
 26 S1 p. S109-
1 p.
 artikel
138 G4.2 Effect of subinhibitory concentrations of antibiotics on the serum sensitivity of wild-type Pseudomonas aeruginosa strains 2005
 26 S1 p. S110-S111
2 p.
 artikel
139 G3.2 Influence of ertapenem on cell activation and co-stimulatory molecule expressions 2005
 26 S1 p. S110-
1 p.
 artikel
140 G2.1 Influence of levofloxacin on proinflammatory cytokines and signal transduction pathways associated with inflammation 2005
 26 S1 p. S109-
1 p.
 artikel
141 G4.3 Invasion of bacteria of the respiratory tract into epithelial cells 2005
 26 S1 p. S111-
1 p.
 artikel
142 G4.1 Microbiology of odontogenic facial space infections 2005
 26 S1 p. S110-
1 p.
 artikel
143 G3.1 Paper-disc immobilized bioluminescence technology (PIBIT): A novel, simple and inexpensive method of determining the antibacterial activity of antiseptics, disinfectants and health-care products 2005
 26 S1 p. S109-S110
2 p.
 artikel
144 ISS1.2 Antifungal treatment without compromise 2005
 26 S1 p. S56-
1 p.
 artikel
145 ISS5.1 Antimicrobial resistance in pathogens causing respiratory tract infections including P. aeruginosa 2005
 26 S1 p. S58-
1 p.
 artikel
146 ISS1. Appropriate antibiotics and antifungal use in the hospital setting (Sponsored by merck sharp and Dohme) 2005
 26 S1 p. S55-S56
2 p.
 artikel
147 ISS4.2 Current treatment guidelines for mixed infections: Diabetic foot infections, intra-abdominal infections, and complicated skin and skin structure infections 2005
 26 S1 p. S58-
1 p.
 artikel
148 ISS3.2 Empiric antibiotic treatment for hospital-acquired pneumonias including ventilator-associated pneumonias 2005
 26 S1 p. S57-
1 p.
 artikel
149 ISS4. Empiric therapy of today's polymicrobial infections — available options and alternatives (Sponsored by Wyeth) 2005
 26 S1 p. S58-
1 p.
 artikel
150 ISS3.3 Hospital antibiotic policies 2005
 26 S1 p. S57-S58
2 p.
 artikel
151 ISS5.3 New treatment strategies in acute bacterial exacerbation of chronic bronchitis 2005
 26 S1 p. S59-
1 p.
 artikel
152 ISS5.2 PK/PD and clinical utility of fluoroquinolones in respiratory tract infections 2005
 26 S1 p. S58-S59
2 p.
 artikel
153 ISS1.1 Role of carbapenem in treating serious bacterial infections 2005
 26 S1 p. S56-
1 p.
 artikel
154 PL2 Emerging viral diseases in Asia: Deciphering the writing on the wall 2005
 26 S1 p. S1-S2
2 p.
 artikel
155 PL5 Gene tricks to escape antibiotics 2005
 26 S1 p. S4-
1 p.
 artikel
156 PL4 Grand strategies for cancer management 2005
 26 S1 p. S3-S4
2 p.
 artikel
157 PL3 Health care response to HIV in the third world: Challenges and strategies 2005
 26 S1 p. S2-S3
2 p.
 artikel
158 PL1 H. umezawa memorial lecture 2005
 26 S1 p. S1-
1 p.
 artikel
159 PL6.4. Statement from the Asia Pacific society for medical virology (APSMV) 2005
 26 S1 p. S6-
1 p.
 artikel
160 PL6.6. Statement from the Philippine partnership to fight tuberculosis, Malaria, and AIDS 2005
 26 S1 p. S7-
1 p.
 artikel
161 PL6.5. Statement from the Philippine retinoblastoma cooperative group 2005
 26 S1 p. S6-S7
2 p.
 artikel
162 PL6.1. Statement on antibiotic use and antimicrobial resistance 2005
 26 S1 p. S5-
1 p.
 artikel
163 PL6.3. Statement on innovations in infection control in resource-constrained areas 2005
 26 S1 p. S6-
1 p.
 artikel
164 PL6.2. Statement on the politics of TB drug development 2005
 26 S1 p. S5-S6
2 p.
 artikel
165 RTD1.2 Behavioral interventions for improving rational drug use among physicians and patients 2005
 26 S1 p. S59-S60
2 p.
 artikel
166 RTD2.3 Current status of drug discovery and development in the private sector 2005
 26 S1 p. S61-
1 p.
 artikel
167 RTD1.4 Global efforts to improve rational drug use 2005
 26 S1 p. S60-
1 p.
 artikel
168 RTD2.1 Ideal drug specifications 2005
 26 S1 p. S60-
1 p.
 artikel
169 RTD1.1 Impact of antibiotic misuse on antimicrobial resistance in developing countries 2005
 26 S1 p. S59-
1 p.
 artikel
170 RTD3.3 Implementing infection control programs: A model for developing countries 2005
 26 S1 p. S61-S62
2 p.
 artikel
171 RTD2.4 Obstacles to new drugs 2005
 26 S1 p. S61-
1 p.
 artikel
172 RTD3.2 Practical interventions to reduce the risk of ventilator-associated pneumonia (VAP) 2005
 26 S1 p. S61-
1 p.
 artikel
173 RTD2.2 Role of the global alliance for TB drug development 2005
 26 S1 p. S60-S61
2 p.
 artikel
174 RTD1.3 Towards rational international antibiotic breakpoints: Actions from the european committee on antimicrobial susceptibility testing (EUCAST) 2005
 26 S1 p. S60-
1 p.
 artikel
175 S16.1 Adjuvant treatment of breast cancer: Do we have a new standard? 2005
 26 S1 p. S34-
1 p.
 artikel
176 S28.3 Advances in the treatment of lung cancer 2005
 26 S1 p. S46-S47
2 p.
 artikel
177 S7.1 AIDS updates 2005
 26 S1 p. S25-
1 p.
 artikel
178 SAL3 Antibiotic resistance: Defining the problem and implementing effective control measures 2005
 26 S1 p. S11-S12
2 p.
 artikel
179 SAL2 Applications of pharmacodynamics in drug development: New and older agents 2005
 26 S1 p. S10-S11
2 p.
 artikel
180 SAL 11 Dengue: Diagnosis, treatment and epidemiology 2005
 26 S1 p. S17-S18
2 p.
 artikel
181 SAL5 Immunomodulatory therapy for infectious diseases 2005
 26 S1 p. S14-
1 p.
 artikel
182 SAL9 Inflammation, aging and neoplasia 2005
 26 S1 p. S15-
1 p.
 artikel
183 SAL10 Lung cancer: From bench to clinic 2005
 26 S1 p. S15-S16
2 p.
 artikel
184 SAL1 Pharmacogenomics and drug discovery: Impact of transporter-mediated disposition and interaction in chemotherapy 2005
 26 S1 p. S9-S10
2 p.
 artikel
185 SAL7 Quality improvement in infection control in resource-constrained settings 2005
 26 S1 p. S14-S15
2 p.
 artikel
186 SAL6 Technological advances in hospital infection control 2005
 26 S1 p. S14-
1 p.
 artikel
187 SAL4 The globalization of multidrug-resistant TB 2005
 26 S1 p. S12-S13
2 p.
 artikel
188 SAL12 The WHO-UNAIDS “3 by 5” initiative: Progress today, issues and challenges for tomorrow 2005
 26 S1 p. S18-S19
2 p.
 artikel
189 S9.3 Amplified resistance in TB 2005
 26 S1 p. S27-
1 p.
 artikel
190 S3.3 Antiretroviral therapy in resource-limited countries 2005
 26 S1 p. S21-S22
2 p.
 artikel
191 S29.3 An update on the prevalence, distribution and treatment of capillariasis Philippinensis 2005
 26 S1 p. S47-S48
2 p.
 artikel
192 S25.4 Appropriate personal protective equipment for isolation 2005
 26 S1 p. S44-
1 p.
 artikel
193 S37.2 Asymptomatic bacteriuria — When to treat 2005
 26 S1 p. S54-
1 p.
 artikel
194 S15.3 Avian influenza A (H5N1): Origins and pathogenesis 2005
 26 S1 p. S33-
1 p.
 artikel
195 S12.4 Bacterial interference — Does it work as a therapy against recurrent symptomatic UTI? 2005
 26 S1 p. S30-
1 p.
 artikel
196 S35.2 Bacterial resistance mechanisms and their detection: MRSA/VISA/VRSA 2005
 26 S1 p. S53-
1 p.
 artikel
197 S8.3 Beta-lactam resistance in enterobacteriaceae 2005
 26 S1 p. S26-
1 p.
 artikel
198 S13.2 Biofilm in chronic broncho-pulmonary infections 2005
 26 S1 p. S30-S31
2 p.
 artikel
199 S1.3 Biofilm in urinary tract infections 2005
 26 S1 p. S19-
1 p.
 artikel
200 S1.4 Biofilm in urinary tract infections — The search for antibiofilm agents 2005
 26 S1 p. S19-S20
2 p.
 artikel
201 S16.2 Biotherapy of breast cancer 2005
 26 S1 p. S34-
1 p.
 artikel
202 S19.4 Can and when should beta-lactams be given by continuous infusion? 2005
 26 S1 p. S37-S38
2 p.
 artikel
203 S13.4 Can macrolides prevent biofilm? 2005
 26 S1 p. S31-
1 p.
 artikel
204 S24.1 Catheter-associated UTI — New aspects 2005
 26 S1 p. S42-
1 p.
 artikel
205 S32.3 Community-acquired pneumonia in Asia 2005
 26 S1 p. S50-
1 p.
 artikel
206 S24.5 Continuous vs. intermittent antibiotic therapy in patients with transient ureteral catheters due to obstructive UTI 2005
 26 S1 p. S43-
1 p.
 artikel
207 S11.1 Convener and chair 2005
 26 S1 p. S28-
1 p.
 artikel
208 S3.1 Cost-effectiveness of prevention of mother-to-child transmission programs 2005
 26 S1 p. S21-
1 p.
 artikel
209 S27.1 Dengue vaccines: A progress report 2005
 26 S1 p. S45-
1 p.
 artikel
210 S23.1 Distinguishing colonization from infection in ventilator-associated pneumonia 2005
 26 S1 p. S41-
1 p.
 artikel
211 S33.3 Do novel agents work? 2005
 26 S1 p. S51-
1 p.
 artikel
212 S19.2 Dose adjustments and ensuring efficacy in urinary tract infections 2005
 26 S1 p. S37-
1 p.
 artikel
213 S19.3 Dose adjustments and fighting the emergence of resistance in pneumococci 2005
 26 S1 p. S37-
1 p.
 artikel
214 S9.4 DOTS-Plus: Country experiences 2005
 26 S1 p. S28-
1 p.
 artikel
215 S9.1 DOTS works 2005
 26 S1 p. S27-
1 p.
 artikel
216 S26.1 Drug resistance in Haemophilus influenzae 2005
 26 S1 p. S44-
1 p.
 artikel
217 S37.5 Duration of antibiotic treatment for acute “non-complicated” pyelonephritis: A systematic approach 2005
 26 S1 p. S55-
1 p.
 artikel
218 S37.4 Economic aspects of therapy 2005
 26 S1 p. S54-S55
2 p.
 artikel
219 S34.1 Efficient induction of prophylactic antibodies against prion disease in mice 2005
 26 S1 p. S51-
1 p.
 artikel
220 S34.4 Emerging infectious diseases in Taiwan: Klebsiella pneumoniae and leptospirosis 2005
 26 S1 p. S52-
1 p.
 artikel
221 S20.4 Engaging the significant others in defusing the time bomb 2005
 26 S1 p. S39-
1 p.
 artikel
222 S21.1 Epidemiology of human papilloma virus: Implications for early detection and management of cervical cancer 2005
 26 S1 p. S39-
1 p.
 artikel
223 S35.1 Epidemiology of resistant gram-positive infections worlwide 2005
 26 S1 p. S52-S53
2 p.
 artikel
224 S22. Epidemiology, pathogenesis and overview of hepatitis — An update 2005
 26 S1 p. S40-
1 p.
 artikel
225 S1.2 Experimental and clinical experience with rifampicin-coated devices 2005
 26 S1 p. S19-
1 p.
 artikel
226 S26.3 Extended-spectrum β-lactams (ESBLS) 2005
 26 S1 p. S45-
1 p.
 artikel
227 S5.1 Fungal infections in neutropenic patients 2005
 26 S1 p. S23-
1 p.
 artikel
228 S5.4 Fungal infections: New treatment options 2005
 26 S1 p. S23-S24
2 p.
 artikel
229 S6.2 Healthcare worker safety and welfare: Responsibility of the hospital administration 2005
 26 S1 p. S24-
1 p.
 artikel
230 S6.3 Healthcare worker safety and welfare: Responsibility of the hospital administration 2005
 26 S1 p. S24-
1 p.
 artikel
231 S12.2 High biofilm productivity in Escherichia coli isolated from prostatitis 2005
 26 S1 p. S29-
1 p.
 artikel
232 S32.1 H5N1 and SARS — What have we learned? 2005
 26 S1 p. S49-S50
2 p.
 artikel
233 S15.2 Human avian influenza in Thailand 2005
 26 S1 p. S33-
1 p.
 artikel
234 S20.1 Immunology of TB 2005
 26 S1 p. S38-
1 p.
 artikel
235 S14.1 Infectious diseases in mass gatherings (Hajj) 2005
 26 S1 p. S31-
1 p.
 artikel
236 S15.1 Influenza A (H5N1) in asia: Current situation and WHO responses 2005
 26 S1 p. S33-
1 p.
 artikel
237 S27.3 Influenza vaccines 2005
 26 S1 p. S45-S46
2 p.
 artikel
238 S36. Interactive session on clinical infections 2005
 26 S1 p. S53-
1 p.
 artikel
239 S30.1 International outbreak related research: A research ethics perspective 2005
 26 S1 p. S48-
1 p.
 artikel
240 S2.1 Interventions to promote appropriate use of antibiotics: Why surveillance is not enough? 2005
 26 S1 p. S20-
1 p.
 artikel
241 S19.1 Introduction: The pharmacological and microbiological basis of PK/PD: Why did we need to invent PK/PD in the first place? 2005
 26 S1 p. S36-S37
2 p.
 artikel
242 S17.1 Issues and concerns in the management of healthcare-associated pneumonia in the Philippines 2005
 26 S1 p. S34-S35
2 p.
 artikel
243 S6.4 Issues and concerns of hepatitis B carriers 2005
 26 S1 p. S24-S25
2 p.
 artikel
244 S3.2 Issues on drug resistance testing in relation to antiretroviral clinical management 2005
 26 S1 p. S21-
1 p.
 artikel
245 S5.2 Is there in vivo-in vitro correlation between antifungal susceptibility, species of Candida spp. and clinical outcome? 2005
 26 S1 p. S23-
1 p.
 artikel
246 S27.2 Japanese encephalitis vaccines 2005
 26 S1 p. S45-
1 p.
 artikel
247 S37.1 Kidney disease and UTI 2005
 26 S1 p. S54-
1 p.
 artikel
248 S28.4 Lung cancer differentiation and targeted therapies 2005
 26 S1 p. S47-
1 p.
 artikel
249 S23.4 Macrolide therapy in diffuse panbronchiolitis 2005
 26 S1 p. S41-S42
2 p.
 artikel
250 S8.4 Metallo-β-lactamases in imipenem-resistant Acinetobacter and Pseudomonas spp and emergence of a novel SIM-1 enzyme 2005
 26 S1 p. S26-S27
2 p.
 artikel
251 S2.3 Microbiological risks associated with antimicrobial drug use in food-producing animals 2005
 26 S1 p. S21-
1 p.
 artikel
252 S8.1 Molecular evolution in antimicrobial resistance genes of Shigella sonnei isolated in Korea 2005
 26 S1 p. S26-
1 p.
 artikel
253 S23.3 Molecular pathogenesis of legionnaire's disease 2005
 26 S1 p. S41-
1 p.
 artikel
254 S33.1 Multidrug-resistant Acinetobacter baumanii and Pseudomonas aeruginosa 2005
 26 S1 p. S50-S51
2 p.
 artikel
255 S26.2 Multi-drug resistant enterobacteriaceae 2005
 26 S1 p. S44-
1 p.
 artikel
256 S6.1 Needlestick injuries: Chemoprophylaxis and barrier protection 2005
 26 S1 p. S24-
1 p.
 artikel
257 S22.3 Neonatal immune response-based method for prevention of infantile development of HBV carrier-state 2005
 26 S1 p. S40-
1 p.
 artikel
258 S5.3 New antifungal agents 2005
 26 S1 p. S23-
1 p.
 artikel
259 S35.3 New targets and approaches to antimicrobial therapy 2005
 26 S1 p. S53-
1 p.
 artikel
260 S29.4 New treatment for visceral leishmaniasis 2005
 26 S1 p. S48-
1 p.
 artikel
261 S34.2 Nipah virus: A re-emerging chameleon pathogen 2005
 26 S1 p. S52-
1 p.
 artikel
262 S12.1 Nosocomial infections by Staphylococcus epidermidis: How a commensal bacterium turns into a (uro) pathogen 2005
 26 S1 p. S29-
1 p.
 artikel
263 S24.4 Nosocomial UTI, driving force of antibiotic resistance 2005
 26 S1 p. S43-
1 p.
 artikel
264 S15.4 Pandemic planning and influenza vaccines 2005
 26 S1 p. S33-S34
2 p.
 artikel
265 S17.2 Pan-resistant bugs (A. baumanii and P. aeruginosa): Antimicrobial therapy and infection control 2005
 26 S1 p. S35-
1 p.
 artikel
266 S7.2 Pathogenesis of RSV infections: New insights 2005
 26 S1 p. S25-
1 p.
 artikel
267 S12.5 Pharmacokinetic and pharmacodynamic aspects of the treatment of uncomplicated UTI 2005
 26 S1 p. S30-
1 p.
 artikel
268 S17.3 PK/PD in the treatment of hospital-acquired pneumonia 2005
 26 S1 p. S35-
1 p.
 artikel
269 S17.4 Preparing for emerging nosocomial pathogens: Lessons from SARS in singapore 2005
 26 S1 p. S35-
1 p.
 artikel
270 S23.2 Preventing the bacterial pneumonia and other complications of influenza 2005
 26 S1 p. S41-
1 p.
 artikel
271 S12.3 Preventive effect of lactobacillus vaginal suppositories on recurrence of urinary tract infection 2005
 26 S1 p. S29-
1 p.
 artikel
272 S9.2 Private public mix DOTS: The Philippine experience 2005
 26 S1 p. S27-
1 p.
 artikel
273 S8.2 Quinolone resistance among enterobacteriaceae in Korea 2005
 26 S1 p. S26-
1 p.
 artikel
274 S18.2 Reducing pneumonia-related mortality in a low-resource, HIV endemic country: The Malawi CLH project 2005
 26 S1 p. S36-
1 p.
 artikel
275 S34.5 Re-emerging incapacitating viral diseases in Indonesia 2005
 26 S1 p. S52-
1 p.
 artikel
276 S1.5 Regulatory effects of macrolides on bacterial biofilm and virulence: Potential role as quorum-sensing inhibitors 2005
 26 S1 p. S20-
1 p.
 artikel
277 S4.1 Retinoblastoma profile in the Philippines 2005
 26 S1 p. S22-
1 p.
 artikel
278 S4.2 Retinoblastoma: The Indian (tata memorial hospital) experience 2005
 26 S1 p. S22-
1 p.
 artikel
279 S30.2 Risk infections and bioterrorism 2005
 26 S1 p. S48-S49
2 p.
 artikel
280 S20.2 Role of immunotherapy in TB 2005
 26 S1 p. S38-
1 p.
 artikel
281 S14.2 Role of travel in the spread of antibiotic resistance 2005
 26 S1 p. S32-
1 p.
 artikel
282 S29.2 Roll back malaria (RBM) control program 2005
 26 S1 p. S47-
1 p.
 artikel
283 S32.2 SARS — Future perspectives from past experiences 2005
 26 S1 p. S50-
1 p.
 artikel
284 S22.2 Serological and molecular advances in clinical laboratory testing for hepatitis viruses 2005
 26 S1 p. S40-
1 p.
 artikel
285 S30.3 Severe acute respiratory syndrome 2005
 26 S1 p. S49-
1 p.
 artikel
286 S14.3 Sexually transmitted infections (STI) in the age of global travel 2005
 26 S1 p. S32-
1 p.
 artikel
287 S1.1 Silver as antimicrobial substance in biomaterials 2005
 26 S1 p. S19-
1 p.
 artikel
288 S31.2 Surveillance: The basics during an outbreak 2005
 26 S1 p. S49-
1 p.
 artikel
289 S31.1 Surveillance: Utilizing statistical process control charts and feedback mechanisms in reducing resistant organisms and healthcare-associated infections 2005
 26 S1 p. S49-
1 p.
 artikel
290 S20.3 TB vaccine 2005
 26 S1 p. S39-
1 p.
 artikel
291 S10.1 The importance of and obstacles to conducting clinical trials in developing countries 2005
 26 S1 p. S28-
1 p.
 artikel
292 S24.3 The pan-European and the pan euro-asian prevalence studies on nosocomially acquired urinary tract infections (NAUTI) 2005
 26 S1 p. S42-S43
2 p.
 artikel
293 S19.5 The pharmacokinetics and pharmacodynamics of anti-malarials: A new approach in the treatment of malaria: The Philippine experience 2005
 26 S1 p. S38-
1 p.
 artikel
294 S13.3 The relevance of catheter material for nosocomial UTI 2005
 26 S1 p. S31-
1 p.
 artikel
295 S38.3 The value of undertaking an infection control audit 2005
 26 S1 p. S55-
1 p.
 artikel
296 S4.4 Treatment approaches for retinoblastoma 2005
 26 S1 p. S22-
1 p.
 artikel
297 S28.2 Tuberculosis and lung cancer: Problems in early detection and issues in cancer management 2005
 26 S1 p. S46-
1 p.
 artikel
298 S14.4 Tuberculosis and travel 2005
 26 S1 p. S32-
1 p.
 artikel
299 S25.1 Understanding transmission-based isolation precautions: An update 2005
 26 S1 p. S43-
1 p.
 artikel
300 S29.1 Update on the management of malaria 2005
 26 S1 p. S47-
1 p.
 artikel
301 S24.2 Urinary catheter associated infections in the elderly 2005
 26 S1 p. S42-
1 p.
 artikel
302 S2.2 Use of PK/PD principles as basis in the selection of antibiotics for therapy 2005
 26 S1 p. S20-S21
2 p.
 artikel
303 S37.3 UTI caused by fluoroquinolone and cephem-resistant enterobacteriaceae 2005
 26 S1 p. S54-
1 p.
 artikel
304 S18.3 Vaccine field studies for childhood pneumonia in the Philippines: The Bohol project 2005
 26 S1 p. S36-
1 p.
 artikel
305 S18.1 Vaccine-preventable pneumonia in children 2005
 26 S1 p. S35-S36
2 p.
 artikel
306 S25.2 Ventilation isolation — The right way at the right time 2005
 26 S1 p. S43-S44
2 p.
 artikel
307 S27.4 West nile virus vaccines 2005
 26 S1 p. S46-
1 p.
 artikel
308 S7.3 What can we gain by annual influenza vaccination? 2005
 26 S1 p. S25-S26
2 p.
 artikel
309 S13.1 What is a biofilm? 2005
 26 S1 p. S30-
1 p.
 artikel
310 S33.2 What's left against pan-resistant bugs? 2005
 26 S1 p. S51-
1 p.
 artikel
311 W2.3 Basic data elements in cancer clinical trials 2005
 26 S1 p. S63-
1 p.
 artikel
312 W3.2 Error detection and correction in data collection 2005
 26 S1 p. S63-
1 p.
 artikel
313 W3.3 Improving quality assurance by using information technology 2005
 26 S1 p. S63-
1 p.
 artikel
314 W2.2 Managing source documents and maintaining data collection records 2005
 26 S1 p. S62-S63
2 p.
 artikel
315 W3.1 Requirements for quality assurance 2005
 26 S1 p. S63-
1 p.
 artikel
316 W1.1 The research team 2005
 26 S1 p. S62-
1 p.
 artikel
317 W1.2 The role and responsibilities of on-site and off-site data managers in clinical trials 2005
 26 S1 p. S62-
1 p.
 artikel
318 W2.1 Using protocol documents 2005
 26 S1 p. S62-
1 p.
 artikel
                             318 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland